GoodRx Holdings (GDRX) Cost of Revenue (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Cost of Revenue data on file, last reported at $20.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue rose 50.82% year-over-year to $20.2 million; the trailing twelve-month figure through Mar 2026 stood at $64.4 million (up 31.11% YoY), and the FY2025 full-year result was $57.6 million, up 19.46% from the prior year.
• Cost of Revenue advanced to $20.2 million in Q1 2026, from $17.5 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $20.2 million in Q1 2026 to a low of $11.7 million in Q3 2024.
• A 5-year average of $15.2 million and a median of $15.2 million in 2023 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue jumped 62.71% in 2022 and tumbled 37.59% in 2024, its largest moves.
• Tracing GDRX's Cost of Revenue over 5 years: stood at $17.4 million in 2022, then slipped by 12.62% to $15.2 million in 2023, then decreased by 19.62% to $12.2 million in 2024, then soared by 43.23% to $17.5 million in 2025, then gained by 15.41% to $20.2 million in 2026.
• Business Quant data shows GDRX's Cost of Revenue at $20.2 million in Q1 2026, $17.5 million in Q4 2025, and $13.4 million in Q3 2025.